Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Recognizing, managing, and adapting to nerve damage caused by cancer treatment

Key Points

• CIPN causes numbness, tingling, and pain in a glove-and-stocking distribution, typically in the hands and feet.
• Oxaliplatin, cisplatin, paclitaxel, docetaxel, vincristine, bortezomib, and thalidomide are the most common causative agents.
• Duloxetine (Cymbalta) is the only agent with strong RCT evidence for treating established CIPN.
• Cryotherapy (cold gloves/socks during taxane infusion) may reduce CIPN severity — discuss with your oncologist.
• Dose modification or discontinuation is sometimes necessary; report worsening symptoms promptly to allow timely adjustments.
• Fall prevention is critical — compromised sensation and proprioception significantly increase injury risk.

What Is CIPN?

Chemotherapy-induced peripheral neuropathy (CIPN) is damage to the peripheral nervous system — the nerves outside the brain and spinal cord — caused by certain cancer treatments. It is one of the most common and potentially long-lasting side effects of cancer therapy, affecting up to 68% of patients during treatment and persisting in 30% at 6 months. Sensory neuropathy (most common) produces numbness, tingling, "pins and needles" (paresthesias), burning pain, and loss of proprioception (the sense of body position) in a symmetric, length-dependent "glove-and-stocking" distribution. Symptoms…

Which Agents Cause CIPN?

Several major classes of chemotherapy are neurotoxic: Platinum compounds: Oxaliplatin is the most acutely symptomatic — it causes a distinctive cold-triggered dysesthesia (touching cold objects produces painful "electric" sensations in the hands and feet) that begins during or immediately after infusion and resolves within days. Cumulative oxaliplatin exposure causes a chronic sensory neuropathy that often persists after treatment ends. Cisplatin causes predominantly sensory neuropathy that is dose-dependent, may be irreversible, and can worsen for months after stopping the drug ("coasting"…

Prevention Strategies

Despite decades of research, no neuroprotective agent has been proven effective in rigorous trials. Several strategies are used in clinical practice: Cryotherapy: Wearing frozen gloves and frozen socks during taxane chemotherapy infusions induces local vasoconstriction, reducing drug delivery to peripheral nerve endings. Multiple RCTs support its use for paclitaxel, with meta-analyses showing meaningful reduction in CIPN severity and incidence. The DigniCap principle is extended here: cold reduces local exposure. Cryotherapy is less well-studied for oxaliplatin (where cold paradoxically…

Treatment of Established CIPN

Duloxetine (Cymbalta) is the only pharmacological agent with strong RCT evidence for treating established CIPN. The ASCO-endorsed Phase III CCOP trial (Smith et al., J Clin Oncol 2013) demonstrated that duloxetine 60mg daily significantly reduced pain in patients with cisplatin- or paclitaxel-induced painful neuropathy. It is the recommended first-line pharmacological agent per ASCO 2014 and 2020 guidelines. Starting dose 30mg daily for one week, then 60mg; allow 4–6 weeks for full effect. Gabapentin and pregabalin are widely prescribed for neuropathic pain in other conditions (diabetic…

Living with CIPN

For patients with persistent CIPN, adapting daily life to maximize safety and function is critically important: Fall prevention: CIPN-related proprioceptive loss significantly increases fall risk, especially in older adults. Install grab bars in bathrooms and handrails on stairs. Use non-slip mats in the shower. Ensure adequate lighting throughout the home, especially at night. Consider a night light and clear pathways to the bathroom. Wear supportive, well-fitting footwear with a grip sole — avoid going barefoot or wearing slippers. Foot care: Inspect feet daily for blisters, sores, or…